News & Views

Adobestock 550344920

LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates

Expanded agreement grants Iksuda access to Legochem Biosciences’ next generation ADC platform for up to six targets

Adobestock 427889993

Iksuda Therapeutics closes $47 million financing round

• Funding to accelerate clinical progression of Iksuda’s pipeline of new generation of antibody drug conjugates, targeting tumours with high unmet need • Investment round led by Korean-based Mirae Asset Capital and Celltrion

Sign up for more news

Thank you
*required field
*required field
*required field
I confirm that I have read the data protection and Privacy Policy and that I agree to the processing of my personal data